Trazodone in Adults 65 and Older: Off-Label Uses, Doses, and Safety

What Is Trazodone and Why Is It Used Off-Label in Older Adults?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder. Its strong histamine H1 and alpha-1 adrenergic antagonism at doses below 150 mg produces sedation without the anticholinergic burden of older tricyclic antidepressants, making it an attractive option in patients over 65 who cannot tolerate first-line hypnotics.

The Gap Between Approval and Practice

The FDA label for trazodone (brand name Desyrel, now mostly generic) has never included insomnia as an indication. Despite that, a 2017 analysis published in the British Journal of Clinical Pharmacology found trazodone was the second most dispensed medication for insomnia in the United States, trailing only zolpidem, with off-label prescribing particularly concentrated in older adults (1).

Why Geriatric Patients Are Prescribed It Off-Label

Older adults metabolize sedative-hypnotics differently. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) carry explicit Beers Criteria warnings because of cognitive impairment, dependence, and fracture risk. The 2023 American Geriatrics Society Beers Criteria lists benzodiazepines and non-benzodiazepine receptor agonists as potentially inappropriate in adults 65 and older (2). Trazodone, by contrast, is not a controlled substance and does not act on GABA receptors, which drives its appeal as a prescribing alternative even though the evidence base for sleep in older adults remains limited.

Off-Label Uses of Trazodone in Patients Over 65

Insomnia

The most common off-label application. A randomized controlled trial published in JAMA (Roth et al., N=306) demonstrated that trazodone 50 mg at bedtime significantly improved sleep latency and total sleep time compared with placebo over two weeks in adults with primary insomnia, though the trial population was not restricted to older adults (3). Longer-term data specifically in geriatric populations remain sparse.

Trazodone's sedative mechanism at low doses differs from its antidepressant action. Below 150 mg, H1 and alpha-1 blockade dominate, producing sleep onset without the full serotonin reuptake inhibition needed for antidepressant effect. This pharmacological split is why 25 to 100 mg is considered the functional off-label dose range for insomnia in elderly patients.

Agitation and Behavioral Disturbance in Dementia

Agitation affects approximately 30 to 50% of people with Alzheimer's disease at some stage of illness (4). Antipsychotics carry FDA black-box warnings for increased mortality in elderly patients with dementia-related psychosis. Trazodone has been studied as a gentler alternative.

A double-blind trial by Sultzer et al. (N=28) compared trazodone with haloperidol and behavior management in agitated patients with dementia. Both active treatments outperformed placebo on the Agitation Behavior Mapping Instrument, and trazodone produced fewer extrapyramidal side effects than haloperidol (5). The effect sizes were modest, and the sample was small, but the tolerability profile supported trazodone's continued off-label use.

Sundowning Associated with Dementia

"Sundowning," the pattern of late-afternoon and evening confusion or agitation in dementia, is closely tied to circadian rhythm disruption. Trazodone 50 mg given at dusk may reduce nighttime wakefulness and evening agitation by advancing sleep pressure. A pilot randomized controlled trial by McCurry et al. Found that behavioral interventions combined with sleep-focused pharmacotherapy improved nighttime sleep in community-dwelling adults with Alzheimer's disease, though trazodone alone was not the sole variable (6).

Anxiety and Adjustment Disorders

Some geriatric psychiatrists prescribe trazodone 50 to 100 mg at bedtime for older adults with generalized anxiety whose sleep is severely disrupted and who cannot tolerate SSRIs initially. No large randomized controlled trial has confirmed efficacy specifically for anxiety in adults over 65, and this application remains anecdotal and based on pharmacological reasoning rather than high-grade evidence.

Pharmacokinetics in the Geriatric Population

Aging changes trazodone's pharmacokinetics in ways that increase exposure and extend duration of action. Understanding these shifts is necessary for safe dosing.

Absorption and Distribution

Trazodone is well absorbed orally (bioavailability approximately 65 to 70%) and is highly protein-bound (89 to 95%). Older adults often have lower serum albumin, which can increase the free fraction of the drug and intensify both therapeutic and adverse effects at standard doses. A PubMed-indexed pharmacokinetics review confirms that protein binding changes in elderly patients alter effective drug concentrations for highly bound agents (7).

Metabolism and Half-Life

Trazodone is primarily metabolized by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP). CYP3A4 activity declines with age. The result: elimination half-life increases from approximately 5 to 9 hours in younger adults to 10 to 12 hours or longer in patients over 65. Clinically, this means morning sedation ("hangover") is more likely in elderly patients even at doses that seem reasonable at bedtime.

Renal Clearance

Trazodone's renal excretion is minor, so creatinine clearance does not drive dose adjustment directly. The main concern is the downstream effect of renal impairment on albumin and acid-base status, both of which influence protein binding.

Dosing Guidelines for Older Adults

No FDA-approved dosing protocol exists specifically for off-label geriatric use, so recommendations draw from geriatric pharmacology consensus documents and clinical trial data.

Starting Dose

Most geriatric pharmacology references recommend starting at 25 mg at bedtime. The 2019 consensus statement from the American Association for Geriatric Psychiatry (AAGP) supports cautious initiation with gradual titration in older patients to minimize orthostatic events (8).

Titration Schedule

A common approach is to increase by 25 mg every 5 to 7 days as tolerated. For insomnia, most patients respond between 50 to 100 mg at bedtime. For adjunctive management of agitation in dementia, doses of 50 to 200 mg/day (divided or at bedtime) are reported in the literature, though doses above 100 mg in frail elderly patients warrant close monitoring.

Maximum Practical Dose for Off-Label Sedation

The FDA-approved maximum for depression is 400 mg/day (outpatient) or 600 mg/day (inpatient). For off-label geriatric sedation, exceeding 150 mg at bedtime is rarely justified and substantially increases fall risk without proportional benefit.

Geriatric Trazodone Dose Ladder (Off-Label Sedation)

| Week | Dose | Goal | |------|------|------| | 1 | 25 mg QHS | Tolerability check | | 2 to 3 | 50 mg QHS | Sleep onset improvement | | 4 to 6 | 75 to 100 mg QHS | Sleep maintenance optimization | | 7+ | Up to 150 mg QHS | Only if 100 mg insufficient and orthostasis absent |

Safety Profile and Adverse Effects in Older Adults

Orthostatic Hypotension and Falls

The most clinically significant risk in patients over 65 is orthostatic hypotension from alpha-1 adrenergic blockade. A 2014 cohort study in JAMA Internal Medicine (N=1,945 nursing home residents) found that trazodone use was associated with a statistically significant increase in fall-related injuries compared with non-use (adjusted odds ratio 1.54, 95% CI 1.13 to 2.09, P<0.01) (9). This finding does not mean trazodone should never be used, but it does mean standing blood pressure must be measured at baseline and after each dose increase.

Morning Sedation and Cognitive Effects

Because of the extended half-life in elderly patients, residual sedation the following morning is common. Patients should be warned against driving or operating machinery until they know how trazodone affects them the next day. Cognitive screening with validated tools such as the Montreal Cognitive Assessment (MoCA) at baseline and at 3 months is reasonable practice in patients over 75.

QTc Prolongation

Trazodone carries a small but real risk of QTc prolongation. The FDA's comprehensive in vitro proarrhythmia assay program has flagged trazodone as a drug with moderate QTc risk (10). In older adults with pre-existing cardiac disease, a baseline ECG and reassessment after reaching maintenance dose is prudent.

Serotonin Syndrome Risk

Polypharmacy is near-universal in adults over 65. Trazodone adds serotonergic load, and combining it with SSRIs, SNRIs, tramadol, linezolid, or monoamine oxidase inhibitors can precipitate serotonin syndrome. The Hunter Serotonin Toxicity Criteria define the clinical diagnostic threshold: clonus, agitation, diaphoresis, tremor, and hyperreflexia appearing after a serotonergic combination (11).

Priapism

Rare but documented. Alpha-1 blockade can cause prolonged erection. Older men with benign prostatic hypertrophy who are already on alpha-blockers (tamsulosin, terazosin) face an additive alpha-blockade risk that should be discussed during informed consent.

The Beers Criteria Position on Trazodone

The 2023 AGS Beers Criteria do not list trazodone as an explicitly inappropriate drug for older adults the way they list benzodiazepines or anticholinergics. However, the criteria do flag all sedating medications for fall and fracture risk, and the orthostasis data cited above place trazodone in a category requiring caution rather than avoidance (2).

The Beers panel's position is nuanced: trazodone may be preferable to benzodiazepines for short-term sleep disturbance in older adults because it lacks dependence potential, but prescribers must weigh the orthostatic and sedation risks against those of the alternative. As stated in the 2023 update, "the risk-benefit assessment for sedating non-benzodiazepine agents in older adults must be individualized based on fall history, cardiovascular status, and cognitive baseline."

Drug Interactions Relevant to Geriatric Polypharmacy

Patients over 65 take an average of 5.8 prescription medications simultaneously (12). Trazodone has several interaction classes that frequently appear in geriatric medication lists.

CYP3A4 Inhibitors

Drugs that inhibit CYP3A4 (fluconazole, clarithromycin, diltiazem, verapamil, grapefruit juice in large quantities) substantially increase trazodone plasma levels. A patient stable on 100 mg trazodone who begins a 10-day course of clarithromycin for pneumonia may effectively be receiving a 200 to 250 mg equivalent dose. Dose reduction of 50% during strong CYP3A4 inhibitor co-administration is a reasonable precaution.

CYP3A4 Inducers

Rifampin, carbamazepine, and phenytoin accelerate trazodone metabolism and may render the dose ineffective. Carbamazepine is sometimes used in dementia-related behavioral disturbance, creating a clinically relevant interaction where both drugs share an indication.

Antihypertensives

Alpha-1 blockers and diuretics compound trazodone's orthostatic effect. Evening dosing of trazodone with morning antihypertensive dosing can help reduce the overlap in peak blood pressure effects.

CNS Depressants

Opioids, gabapentinoids, and antihistamines add CNS depression. In older adults, combinations of three or more CNS depressants significantly increase fall and respiratory depression risk, as documented in the FDA's 2016 black-box warning on concurrent opioid and CNS depressant prescribing (13).

Comparing Trazodone to Other Off-Label Sleep Agents in Older Adults

Several pharmacological options compete with trazodone for off-label insomnia management in elderly patients. Understanding the trade-offs helps clinicians make individualized decisions.

Trazodone vs. Mirtazapine

Mirtazapine (7.5 to 15 mg at bedtime) is an NaSSA antidepressant with potent H1 antagonism and an established appetite-stimulating effect. In undernourished elderly patients, mirtazapine may offer dual benefit. A Cochrane review of pharmacological treatments for insomnia found insufficient RCT data to declare either agent superior for sleep specifically in older adults (14). Mirtazapine carries its own orthostatic and weight-gain risks.

Trazodone vs. Low-Dose Doxepin

Doxepin 3 to 6 mg (Silenor) is the only tricyclic-derived agent with FDA approval for sleep maintenance insomnia. At these micro-doses, anticholinergic burden is minimal and the Beers Criteria do not flag it at doses at or below 6 mg. A 12-week RCT (N=240) showed doxepin 6 mg significantly improved sleep maintenance vs. Placebo without next-morning cognitive impairment (15). For patients primarily bothered by early-morning awakening, low-dose doxepin may have a more targeted evidence base than trazodone.

Trazodone vs. Melatonin Receptor Agonists

Ramelteon (8 mg at bedtime) acts on MT1 and MT2 melatonin receptors and has no fall signal in Beers Criteria. It is less effective for sleep maintenance than trazodone but carries essentially no orthostatic, QTc, or serotonin syndrome risk. For patients with isolated sleep-onset difficulty and high fall risk, ramelteon is often the preferred first step.

Monitoring Protocol for Geriatric Patients on Off-Label Trazodone

Structured follow-up reduces adverse outcomes and is expected by payers and malpractice reviewers when trazodone is prescribed off-label in patients over 65.

Baseline Assessment

Before prescribing, clinicians should document: resting and standing blood pressure (orthostatic screen), baseline ECG if cardiac history present or QTc-prolonging co-medications exist, fall history in the preceding 12 months, and a medication reconciliation focusing on serotonergic and CYP3A4-interacting drugs.

Week-2 to Week-4 Follow-Up

Repeat orthostatic blood pressure measurement. Ask specifically about morning sedation, new dizziness, and sleep quality using a validated instrument such as the Pittsburgh Sleep Quality Index (PSQI). If standing systolic drops more than 20 mmHg or diastolic more than 10 mmHg, hold further titration.

Three-Month Review

Reassess whether the off-label indication persists. For insomnia, cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment per the American Academy of Sleep Medicine 2017 guideline, and any pharmacotherapy should be considered a bridge while CBT-I is accessed or completed (16). Patients who achieve stable sleep with CBT-I should be tapered off trazodone over 2 to 4 weeks rather than abruptly discontinued.

Tapering and Discontinuation in Older Adults

Trazodone is not physically addictive in the way benzodiazepines are, but abrupt discontinuation after prolonged use can cause rebound insomnia, irritability, and nausea, particularly at antidepressant doses. The recommended taper for geriatric patients is a 25 mg reduction every 1 to 2 weeks. Patients who have been on trazodone for more than 6 months at doses above 100 mg may require a longer, slower taper of 12.5 mg every 2 weeks to avoid rebound.